Dow Up0.39% Nasdaq Up0.12%

AVEO Pharmaceuticals, Inc. (AVEO)

-NasdaqGS
0.92 0.00(0.00%) 2:21PM EST - Nasdaq Real Time Price
ProfileGet Profile for:
AVEO Pharmaceuticals, Inc.
650 East Kendall Street
Cambridge, MA 02142
United States - Map
Phone: 617-299-5000
Website: http://www.aveopharma.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:71

Business Summary 

AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, a biopharmaceutical company, is engaged in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its therapeutic candidates under development program include AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase 1 dose escalation study; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase 2 trial; Tivozanib, an investigational tyrosine kinase inhibitor of various vascular endothelial growth factor receptors; and AV-380 Program, a program focusing on cachexia, a serious and common complication of advanced cancer, as well as a range of chronic diseases that is characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite. AVEO Pharmaceuticals, Inc. has strategic partnerships with St. Vincent’s Hospital Sydney Limited; Kyowa Hakko Kirin; Biogen Idec, Inc.; OSI Pharmaceuticals, Inc.; Centocor Ortho Biotech Inc.; and Merck & Co., Inc. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on AVEO Pharmaceuticals, Inc.

Corporate Governance 
AVEO Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 4; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Tuan Ha-Ngoc , 62
Chief Exec. Officer, Pres and Director
579.00K0.00
Dr. Jeno Gyuris Ph.D., 54
Chief Scientific Officer
380.00K0.00
Mr. Matthew Dallas , 39
Acting Principal Accounting Officer, VP of Fin. and Treasurer
N/AN/A
Mr. Joseph D. Vittiglio Esq., 42
Sr. VP, Gen. Counsel and Sec.
N/AN/A
Dr. Lynda Chin M.D.,
Member of Scientific Advisory Board
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders